spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  amyotrophic lateral sclerosis 

 HSMN NewsFeed - 6 Aug 2024
NeuroTherapia Raises $12.3M in the First Close of its Series B Financing
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 26 Jul 2024
ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 26 Jun 2024
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn(R) Clinical Trial
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 20 Jun 2024
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 17 Jun 2024
Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Apr 2024
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS(R) (edaravone)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 23 Feb 2024
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 18 Dec 2023
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
Regenerative Medicine Neurosurgery Oncology FDA
 HSMN NewsFeed - 24 Oct 2023
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn(R) for the Treatment of ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 18 Oct 2023
BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 12 Jul 2023
BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 27 Mar 2023
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn(R) for the Treatment of ALS
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 9 Mar 2023
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 14 Feb 2023
KeifeRx Appoints Garrett Vygantas, MD, MBA, to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 27 Dec 2022
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 10 Nov 2022
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
Biopharmaceuticals Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 15 Sep 2022
BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn(R) Phase 2 Progressive MS Trial in Multiple Sclerosis Journal
Regenerative Medicine Neurology
 HSMN NewsFeed - 15 Jun 2022
RADICAVA ORS(R) (edaravone) Now Available in the U.S. for the Treatment of ALS
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 18 May 2022
ProJenX Names Life Sciences Industry Veteran Stan E. Abel as CEO
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 21 Mar 2022
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 25 Feb 2022
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 25 Feb 2022
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Feb 2022
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Jan 2022
Nine Square Therapeutics Appoints Robert Paul as CEO
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 5 Jan 2022
Neuvivo Expands Management Team Adding Gregg Fergus, Former President of Ion Torrent, as Head of Strategy and Business Development and to the Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 27 Dec 2021
FDA Authorizes Further NurOwn(R) Dosing Under Expanded Access Program
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 6 Dec 2021
Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Nov 2021
NURTEC(R) ODT Approved In Kuwait For Acute Treatment Of Migraine
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Nov 2021
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 18 Oct 2021
NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Oct 2021
Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases
Biopharmaceuticals Neurology
 HSMN NewsFeed - 14 Sep 2021
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Aug 2021
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
Regenerative Medicine Neurology Venture Capital
 HSMN NewsFeed - 30 Jun 2021
Mitsubishi Tanabe Pharma America Announces EXSERVAN(TM) (riluzole) is Now Available in the U.S. for the Treatment of ALS
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 6 Apr 2021
Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.
Biopharmaceuticals Devices Drug Delivery
 HSMN NewsFeed - 5 Apr 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 Jan 2021
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
Biopharmaceuticals
 HSMN NewsFeed - 15 Dec 2020
Lilly Announces Agreement to Acquire Prevail Therapeutics
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 14 Dec 2020
BrainStorm Announces NurOwn(R) Expanded Access Program
Regenerative Medicine Neurology Product Launch
 HSMN NewsFeed - 23 Nov 2020
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
Regenerative Medicine Neurology
 HSMN NewsFeed - 20 Nov 2020
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Nov 2020
BrainStorm Announces Topline Results from NurOwn(R) Phase 3 ALS Study
Regenerative Medicine Neurology
 HSMN NewsFeed - 15 Oct 2020
Lilly Announces Agreement to Acquire Disarm Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Aug 2020
Clene Nanomedicine Raises Series D Financing of $42.5 Million
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 24 Aug 2020
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
Regenerative Medicine Neurology
 HSMN NewsFeed - 10 Jun 2020
Biohaven Appoints Bob Hugin to its Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 27 May 2020
BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 30 Apr 2020
Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 23 Mar 2020
Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Mar 2020
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Mar 2020
CytRx Corporation Provides Update on Management Change
Biopharmaceuticals Oncology Neurology Personnel
 HSMN NewsFeed - 3 Mar 2020
FDA Grants Rare Pediatric Disease Designation to Stealth BioTherapeutics for Elamipretide for the Treatment of Barth Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Oct 2019
World Renowned Experts Appointed to Skyhawk Therapeutics Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2019
Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Jul 2019
Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 21 May 2019
Mallinckrodt Files Suit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) to Protect Medicaid Patient Access to Acthar(R) Gel
Biopharmaceuticals Reimbursement Litigation
 HSMN NewsFeed - 26 Nov 2018
Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology Drug Delivery FDA
 HSMN NewsFeed - 23 Oct 2018
CavoGene LifeSciences Licenses Novel Gene Therapy for CNS Disorders
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 3 Oct 2018
Rewind Therapeutics Appoints Leading Neuroscience Drug Developer Ian J. Reynolds as Chief Executive Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 21 Aug 2018
ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Apr 2018
Neuraltus Pharmaceuticals Reports Results from Phase 2 NP001 Study in Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Mar 2018
BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 8 Mar 2018
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
Regenerative Medicine Neurology
 HSMN NewsFeed - 22 Feb 2018
Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 5 Feb 2018
BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 23 Jan 2018
Disarm Therapeutics Appoints Thomas Engber as Senior Vice President, Head of Neuropharmacology and Translational Sciences
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 19 Dec 2017
Disarm Therapeutics Appoints Peter Keller Chief Business Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 30 Nov 2017
Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA(R) (edaravone) to U.S. Department of Veterans Affairs National Formulary
Biopharmaceuticals Neurology Reimbursement
 HSMN NewsFeed - 9 Nov 2017
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Nov 2017
BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 16 Oct 2017
BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 2 Oct 2017
Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Aug 2017
First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S.
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 7 Aug 2017
BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 4 Aug 2017
Biohaven Appoints Julia P. Gregory to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 3 Aug 2017
VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate VM202 for Non-Healing Diabetic Foot Ulcers
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 25 Jul 2017
BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 21 Jul 2017
Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 18 Jul 2017
BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 11 Jul 2017
Nuredis Appoints Julie Anne Smith as Chief Executive Officer to Lead Neurodegenerative Disease Company
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 27 Feb 2017
BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 21 Feb 2017
BrainStorm Seeking Approval To Distribute NurOwn(R) in Canada
Regenerative Medicine Neurology Regulatory Distribution
 HSMN NewsFeed - 9 Jun 2016
NUEDEXTA(R) Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other Dementias, Stroke and Traumatic Brain Injury
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 May 2016
Neuralstem Announces Plan of Reorganization to Further Align Business with Strategic Intent
Regenerative Medicine Neurology
 HSMN NewsFeed - 25 Apr 2016
Pharnext Announces the Opening of the First U.S. Study Site for its PLEO-CMT International Pivotal Phase 3 Trial in Charcot-Marie-Tooth Disease Type 1A
Biopharmaceuticals
 HSMN NewsFeed - 26 Feb 2016
Galderma Delivers Innovation In Dermal Fillers With The Launch Of Two First-In-Class FDA Pivotal Phase III Trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 16 Feb 2016
Neuralstem Appoints Richard Daly as President and Chief Executive Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 19 Jan 2016
Amylyx Announces Election of Nobel Laureate Walter Gilbert, PhD, to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 9 Nov 2015
Avalon Ventures Expands Collaboration with GSK and Launches Seventh New Company at COI Pharmaceuticals
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 Jul 2015
Voyager Therapeutics Appoints Michael Higgins to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 24 Mar 2015
StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 3 Sep 2014
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 25 Mar 2014
BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial
Regenerative Medicine Neurology
 HSMN NewsFeed - 25 Jan 2014
Amorfix Announces Retirement of Walter von Wartburg
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jan 2014
Neuralstem Appoints Catherine Angell Sohn To Board Of Directors
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 16 Dec 2013
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 23 Oct 2013
FDA Approves JUVÉDERM VOLUMA(TM) XC
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 6 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 5 Sep 2013
Neuralstem To Raise $4 Million In Registered Direct Offering
Regenerative Medicine Neurology Venture Capital
 HSMN NewsFeed - 3 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 14 Aug 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 14 Jan 2013
Neuralstem Receives FDA Approval To Commence Spinal Cord Injury Trial
Biopharmaceuticals Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 3 Jan 2013
Biogen Idec Reports Top-Line Results from Phase 3 Trial Investigating Dexpramipexole in People with Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Dec 2012
Amarantus BioScience Acquires Neurodegenerative Diagnostic Intellectual Property Portfolio from Power3 Medical Products
Biopharmaceuticals Diagnostics Neurology Acquisitions
 HSMN NewsFeed - 5 Jun 2012
Neuralstem Updates ALS Stem Cell Trial Progress; Emory University Institutional Review Board Approves Amendment
Biopharmaceuticals Regenerative Medicine Neurology
 HSMN NewsFeed - 14 May 2012
Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Apr 2012
BOTOX(R) Cosmetic (onabotulinumtoxinA) Celebrates 10-Year Anniversary of U.S. Food and Drug Administration Approval
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 16 Feb 2012
Adeona Becomes Synthetic Biologics, Inc.
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2011
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
Regenerative Medicine Neurology
 HSMN NewsFeed - 21 Jul 2011
Merz Aesthetics Announces FDA Approval Of XEOMIN(R) (incobotulinumtoxinA) For The Temporary Improvement In The Appearance Of Moderate To Severe Glabellar Lines In Adult Patients
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 14 Jun 2011
Neuralstem Updates ALS Clinical Trial Progress
Regenerative Medicine Neurology
 HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 10 Feb 2011
Cytokinetics Announces Changes to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Feb 2011
Neuralstem Updates ALS Clinical Trial Progress
Regenerative Medicine Neurology
 HSMN NewsFeed - 9 Feb 2011
Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
Biopharmaceuticals Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 31 Jan 2011
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Jan 2011
BrainStorm Appoints Dr. Adrian Harel as Chief Operating Officer and Acting Chief Executive Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 30 Oct 2010
AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Sep 2010
iPierian Announces Second Close of $28 Million Series B Financing
Biopharmaceuticals Regenerative Medicine Venture Capital
 HSMN NewsFeed - 25 Aug 2010
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
Regenerative Medicine
 HSMN NewsFeed - 13 Aug 2010
US WorldMeds Acquires Solstice Neurosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 8 Jul 2010
iPierian Closes $22 Million Series B Financing Led By Google Ventures
Biopharmaceuticals Regenerative Medicine Venture Capital
 HSMN NewsFeed - 22 Jun 2010
Ipsen: Encouraging results of GuidAge(R), large scale European trial conducted in the prevention of Alzheimer's Dementia
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 May 2010
Teva Provides Update on Talampanel for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Mar 2010
Cytokinetics Announces Orphan Drug Designation Granted to CK-2017357 for the Treatment of Amyotrophic Lateral Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 23 Feb 2010
iPierian Appoints Dr. Michael Venuti as President and Chief Scientific Officer
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 8 Feb 2010
Neuraltus Pharmaceuticals Names Andrew Gengos President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jan 2010
Neuralstem Announces First Patient Treated in ALS Stem Cell Trial
Regenerative Medicine Neurology
 HSMN NewsFeed - 19 Jan 2010
PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
Biopharmaceuticals
 HSMN NewsFeed - 13 Jan 2010
FDA Gives TCA Cellular Therapy Green Light to Proceed with First ALS Adult Stem Cell Trial Using Patient's Own Stem Cells
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 21 Sep 2009
Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 24 Aug 2009
BrainStorm Cell Therapeutics Secures Funding to Reach Clinical Trials for ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 16 Mar 2009
CytRx's Arimoclomol Demonstrates Statistically Significant Neurorestorative Results in a Preclinical Embolic Stroke Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Feb 2009
Neuralstem's ALS Trial on Clinical Hold
Regenerative Medicine Neurology
 HSMN NewsFeed - 8 Jan 2009
Howard Feldman Joins Bristol-Myers Squibb as Vice President and Therapeutic Area Head, Global Clinical Research, Neuroscience
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Dec 2008
Targeted Genetics Realigns Product Development Priorities and Implements Cost Reduction Measures
Biopharmaceuticals
 HSMN NewsFeed - 30 Sep 2008
Link Medicine Completes $40 million Series C Financing to Accelerate Development of First Disease-Modifying Treatments for Neurodegenerative Disorders
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 Sep 2008
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Sep 2008
World Renowned ALS Expert From Harvard Medical School and Mass. General Hospital, Dr. Robert H. Brown Jr., Joins BrainStorm Cell Therapeutics Scientific Advisory Board
Regenerative Medicine Personnel
 HSMN NewsFeed - 21 Jul 2008
Insmed Provides Update on IPLEX(TM) Programs
Biopharmaceuticals
 HSMN NewsFeed - 9 Jun 2008
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Apr 2008
Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
Biopharmaceuticals Generics
 HSMN NewsFeed - 14 Apr 2008
Vasogen Announces Implementation of Strategic Restructuring Plan
Biopharmaceuticals
 HSMN NewsFeed - 13 Mar 2008
Teva Provides Update on Glatiramer Acetate 40mg for Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Feb 2008
California Stem Cell, Inc. Concludes Series A Financing
Regenerative Medicine Venture Capital
 HSMN NewsFeed - 22 Jan 2008
Knopp Neurosciences Completes First Series B Financing of $10 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Dec 2007
Ceregene Promotes Dr. Raymond Bartus to Executive Vice President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Dec 2007
Amarin Signs Agreement to Acquire Ester Neurosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 15 Oct 2007
Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 8 Oct 2007
AVANIR Granted Special Protocol Assessment (SPA) From FDA for Confirmatory Phase III Trial of Zenvia in Patients With PBA
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Oct 2007
Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 7 Aug 2007
KineMed and Merck Enter Collaboration in Atherosclerosis
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2007
CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Jun 2007
Ceregene and Genzyme Announce Partnership for the Development and Commercialization of Cere-120 for Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 May 2007
Neuro-Hitech, Inc., Obtains Exclusive License to Combination Drugs for the Treatment of Alzheimer's Disease and Other Serious Neurological Disorders
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 21 May 2007
CytRx Provides Operational Update
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 May 2007
NeuroVista Raises $33.8 Million in Series B Financing
Devices Neurology Venture Capital
 HSMN NewsFeed - 2 May 2007
Dr. John P. Donoghue Presents on Cyberkinetics' BrainGate Neural Interface System in Plenary Session at the AAN Annual Meeting in Boston
Devices Neurology
 HSMN NewsFeed - 30 Apr 2007
Insmed Releases Positive Results from IPLEX Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 22 Mar 2007
Avicena Announces Patient Enrollment in National Institutes of Health (NIH) Phase III Parkinson's Disease Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Jan 2007
Metabolon Expands Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jan 2007
Italian Ministry of Health Requests IPLEX(TM) for Treatment of ALS (Lou Gehrig's Disease)
Biopharmaceuticals Neurology Licensing Distribution
 HSMN NewsFeed - 6 Dec 2006
Avicena Signs Agreement with the National Institute of Neurological Disorders and Stroke for Phase III Trial for Novel Parkinson's Disease Candidate
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Nov 2006
Gladstone Institutes and Merck & Co., Inc. Announce Major Research Collaboration and Exclusive License Agreement in Field of Apolipoprotein (Apo) E
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 31 Oct 2006
CytRx's Arimoclomol Granted Orphan Drug Designation in European Union for Treatment of ALS
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 14 Oct 2006
Cyberkinetics' BrainGate System Enables Thought-Driven Computer Control for First ALS Patient in Pilot Clinical Trial
Devices Neurology
 HSMN NewsFeed - 11 May 2006
Stem Cell Therapeutics Corp. Announces Issuance of Second US Patent
Regenerative Medicine
 HSMN NewsFeed - 9 May 2006
Avicena Announces Phase III ALS Trial Results
Biopharmaceuticals Neurology
Return to NewsFeed  

 Additional items found! 44

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 44 additional stories matching:
amyotrophic lateral sclerosis
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.